The IL27 Knockout T-47D Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population of the human breast ductal carcinoma cell line T-47D, with targeted disruption of the IL27 gene. This polyclonal format maintains a heterogeneous mixture of cells containing diverse gene edits, offering a biologically relevant loss-of-function model while avoiding clonal artifacts. The knockout pool enables robust studies of IL27 signaling without the need for single-cell isolation, providing a practical tool for high-throughput or co-culture assays where population-level effects are studied.
The T-47D host cell line was established from a pleural effusion of a 54-year-old female with infiltrating ductal carcinoma of the breast and is a classic model of luminal A breast cancer, characterized by estrogen receptor (ER) positivity and hormone-dependent growth. These epithelial cells retain key features of the luminal subtype, including expression of luminal cytokeratins and responsiveness to estrogen and progesterone, making them a gold standard for investigating endocrine-related breast cancer biology and the tumor microenvironment.
IL27 encodes the p28 subunit of the IL27 heterodimeric cytokine, which pairs with EBI3 to signal through IL27RA and gp130 (IL6ST). This triggers JAK1/JAK2 activation, STAT1/STAT3 phosphorylation, and induction of T-bet (TBX21) and IL10. Upstream, IL27 is induced by IFNG, TLR4 agonists, and CD40LG; downstream, it regulates TBX21, IL10, IFNG, and SOCS3. Thus, IL27 orchestrates Th1 differentiation and anti-inflammatory responses, crucial for antitumor immunity.
In the context of T-47D ER-positive breast cancer, IL27 knockout enables functional studies of the cytokine??s role in tumor cell signaling and immune modulation. This model helps clarify how loss of IL27 perturbs JAK/STAT transduction, alters expression of downstream regulators like SOCS3, and affects tumor cell proliferation and interactions with immune effectors, contributing to a better understanding of breast cancer immune evasion.
This polyclonal knockout pool is suitable for western blotting to confirm IL27 protein loss, RT-qPCR for transcriptional profiling, ELISA for secreted cytokine measurement, and STAT phosphorylation flow cytometry to assess signaling. Co-culture immune assays allow investigation of tumor-immune crosstalk, and proliferation assays reveal growth effects. These cells facilitate studies in breast cancer immunology, immune checkpoint regulation, cytokine therapy development, and autoimmune disease modeling. For further information, please contact Ascent Research.
